EUMETSAT Moodle

ADCs act like a shuttle, specifically recognizing and binding to well-expressed antigens on tumor cells, delivering cytotoxic drugs via receptor-mediated endocytosis, and releasing toxins in lysosomes to induce apoptosis or cell death through various pathways.

Currently, over 16 ADC drugs are marketed globally, treating various cancers including breast cancer, lymphoma, and lung cancer. More than 200 ADC candidates are in clinical development, expanding beyond traditional targets to emerging antigens (like B7-H3, CLDN18.2) and exploring combination therapies with PD-1 inhibitors.